Aclaris Therapeutics, Inc. (ACRS) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Neal S. Walker	Co-Founder, Chief Executive Officer & Chairman	965,550	1970
Jesse W. Hall	Chief Medical Officer	371,166	1974
Roland Kolbeck	Chief Scientific Officer	492,432	1964
Hugh Davis	President, Chief Operating Officer & Director	555,541	1960
James Loerop	Chief Business Officer	590,160	1965
Kevin Balthaser	Chief Financial Officer	631,710	1987
William C. Roberts	Senior Vice President of Corporate Communications & Investor Relations	0	1969
Meghan Dunsmore	Senior Vice President of Finance	0	N/A
Nina Samra	Senior Vice President of Clinical Operations	0	N/A
Matthew Rothman	General Counsel & Corporate Secretary	0	N/A
Shaun Selness	Senior VP, Head of Discovery & Preclinical Sciences	0	N/A
Steve Tucker	Executive Vice President of Project Leadership	0	N/A
Jon Jacobsen	Senior Vice President of Chemistry	0	N/A

Name

Title

Pay

Year Born

Neal S. Walker

Co-Founder, Chief Executive Officer & Chairman

965,550

1970

Jesse W. Hall

Chief Medical Officer

371,166

1974

Roland Kolbeck

Chief Scientific Officer

492,432

1964

Hugh Davis

President, Chief Operating Officer & Director

555,541

1960

James Loerop

Chief Business Officer

590,160

1965

Kevin Balthaser

Chief Financial Officer

631,710

1987

William C. Roberts

Senior Vice President of Corporate Communications & Investor Relations

1969

Meghan Dunsmore

Senior Vice President of Finance

N/A

Nina Samra

Senior Vice President of Clinical Operations

N/A

Matthew Rothman

General Counsel & Corporate Secretary

N/A

Shaun Selness

Senior VP, Head of Discovery & Preclinical Sciences

N/A

Steve Tucker

Executive Vice President of Project Leadership

N/A

Jon Jacobsen

Senior Vice President of Chemistry

N/A

Description

Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.